Histidyl-tRNA synthetase (HARS) ligates histidine to cognate tRNA molecules, which is required for protein translation. Mutations in HARS cause the dominant axonal peripheral neuropathy Charcot-Marie-Tooth disease type 2W (CMT2W); however, the precise molecular mechanism remains undefined. Here, we investigated three HARS missense mutations associated with CMT2W (p.Tyr330Cys, p.Ser356Asn, and p.Val155Gly). The three mutations localize to the HARS catalytic domain and failed to complement deletion of the yeast ortholog (HTS1). Enzyme kinetics, differential scanning fluorimetry (DSF), and analytical ultracentrifugation (AUC) were employed to assess the effect of these substitutions on primary aminoacylation function and overall dimeric structure. Notably, the p.Tyr330Cys, p.Ser356Asn, and p.Val155Gly HARS substitutions all led to reduced aminoacylation, providing a direct connection between CMT2W-linked HARS mutations and loss of canonical ARS function. While DSF assays revealed that only one of the variants (p.Val155Gly) was less thermally stable relative to wild-type, all three HARS mutants formed stable dimers, as measured by AUC. Our work represents the first biochemical analysis of
INTRODUCTION
With a prevalence of one in 2,500 individuals, Charcot-Marie-Tooth disease (CMT; also referred to as hereditary motor and sensory neuropathy) represents the most common inherited neuromuscular disorder. CMT disease is a heterogeneous group of peripheral neuropathies mainly characterized by muscle weakness and sensory loss in the distal extremities (Skre, 1974) . Several subtypes of CMT have been described, including one form (CMT1) with primary Schwann cell pathology resulting in demyelination and decreased motor nerve conduction velocities (MNCVs), a second form (CMT2) with normal MNCVs but reduced amplitudes of muscle action potentials arising from axonal degeneration, and an intermediate form that has characteristics of both CMT1 and CMT2 (Dyck & Lambert, 1968; Pareyson & Marchesi, 2009a; Pareyson & Marchesi, 2009b; Pareyson, et al., 2009 ).
CMT typically presents in an axon-length-dependent manner with the structures innervated by longer axons affected first. CMT specifically affects the extremities, causing progressive muscle weakening and wasting, decreased sensation, and skeletal deformities. The onset and penetrance of CMT is variable, with many patients experiencing symptoms in the first two decades of life. At the current time, there are no effective treatments for CMT.
Over 80 genes have been linked to CMT, distributed among diverse functional categories (Timmerman, Strickland, & Zuchner, 2014) . Four genes account for the majority of CMT cases, consisting of peripheral myelin protein 22 (PMP22), myelin protein zero (MPZ), and gap junction beta-1 (GJB1), which are linked to CMT1, and mitofusin 2 (MFN2), which is linked to CMT2. In addition to myelin assembly, the diverse cellular processes affected by CMT include cytoskeleton/axonal transport, protein synthesis and quality control, endosomal sorting, mitochondrial function, channel abnormalities, and mRNA/processing transcription (Bird, 1993; Jerath & Shy, 2015) . While the end result of CMTassociated mutations involves impaired Schwann cell or axon dysfunction, the precise mechanisms by which alterations of individual genes bring about these phenotypes is, for many genes, not well understood (Stum et al., 2011; Timmerman et al., 2014) .
Among the genes linked to CMT are the aminoacyl-tRNA synthetases (ARSs), which attach amino acids to cognate tRNAs in the first step of translation (Antonellis & Green, 2008; Ibba & Soll, 2000) .
As essential protein synthesis factors, ARSs are present in all kingdoms and are ubiquitously expressed in all tissues. The human nuclear genome contains 37 ARS genes, of which 17 encode for a cytoplasmic synthetase, 17 encode for a mitochondrial synthetase, and three encode for bi-functional enzymes that charge tRNA in both cellular compartments. Interestingly, 31 ARS genes have been implicated in myriad dominant and recessive human disease phenotypes (MeyerSchuman & Antonellis, 2017; Oprescu, et al., 2017) . Many of the diseases linked to ARS mutations are severe, recessive developmental syndromes that affect multiple organs and tissues, including the central nervous system (Frohlich et al., 2017; Simons et al., 2015; Zhang et al., 2014) . The majority of the disease-associated mutations have a clear loss-of-function effect, which is supported by the associated patient phenotype. For example, many ARS-associated recessive diseases are specific to mitochondrial ARS enzymes and lead to clear defects in the synthesis of electron transport chain protein synthesis and thus mitochondrial ATP output (Abbott, Francklyn, & Robey-Bond, 2014 ).
To date, five genes encoding a cytoplasmic or bi-functional ARS enzyme have been implicated in autosomal dominant CMT disease: glycyl-(GARS; MIM# 600287), tyrosyl-(YARS; MIM# 603623), alanyl-(AARS; MIM# 601065), histidyl-(HARS; MIM# 142810), and tryptophanyl-tRNA synthetase (WARS; MIM# 191050) (Jordanova et al., 2006; Latour et al., 2010; Safka Brozkova et al., 2015; Tsai et al., 2017; Vester et al., 2013) . Methionyl-tRNA synthetase (MARS) variants have been identified in patients with peripheral neuropathy (Gonzalez et al., 2013; Hirano et al., 2016; Hyun et al., 2014; Nam et al., 2016) .
However, these variants were identified in single individuals or small families deeming the findings inconclusive. The first ARS implicated in CMT disease was GARS, where mutations were implicated in axonal CMT disease via positional cloning in families with an atypical disease presentation (Antonellis et al., 2003; Sivakumar et al., 2005) . Notably, the majority of patients presented with an upper limb predominant neuropathy that affected the intrinsic muscles of the hand (Antonellis et al., 2003; Sivakumar et al., 2005) . Subsequently, YARS, AARS, HARS, and WARS mutations were identified in families with a more typical presentation of CMT disease (Jordanova et al., 2006; Latour et al., 2010; Safka Brozkova et al., 2015; Tsai et al., 2017; Vester et al., 2013) .
HARS is unusual among the ARS in that different mutations in the gene encoding the cytoplasmic enzyme lead to two distinct inherited neurological syndromes. Initially, a single HARS mutation (P.Tyr454Ser) in the homozygous state was linked to recessive Usher Syndrome Type 3B in a small number of Amish children presenting with early onset loss of auditory and visual function (Puffenberger et al., 2012 ) (Abbott et al., 2017) . Initial characterization of the mutant enzyme did not reveal a significant loss of aminoacylation, change in expression level, or change in intracellular localization. Subsequently, a candidate gene screen of 363 patients with CMT disease and no other previously acknowledged existing disease-causing alleles identified a HARS missense mutation (R137Q) in a single patient with peripheral neuropathy (Vester et al., 2013) . More definitive evidence linking HARS mutations to CMT disease was provided by the identification of multigenerational pedigrees with inherited peripheral neuropathy that segregated with HARS missense mutations (T132I, P134H, D175E, and D364Y) (Safka Brozkova et al., 2015) . While previous studies demonstrated consequences of HARS mutations consistent with pathogenicity, biochemical analyses on the primary function of HARS have yet to be performed.
Here, we report detailed biochemical analyses of HARS missense mutations identified in three families with autosomal dominant CMT disease. As part of our study, each mutant protein was expressed, purified, and characterized biochemically. The results indicate that each of the three mutations leads to a clear reduction in HARS catalytic activity. These findings provide the first indication that a substantial decrease in HARS catalytic activity is associated with CMT disease.
The results are discussed in light of current models linking altered ARS activity to CMT pathophysiology. 
MATERIALS AND METHODS

Clinical and genetic analysis of patients
Family 2
All family members were studied at Bellvitge's University Hospital.
Detailed neurological evaluation was performed on patients and unaffected subjects. Electrophysiological studies were performed using standard methods in all subjects. We classified the severity of neuropathy symptoms according to the CMT neuropathy score (CMTNS).
Blood samples were obtained from all family members once informed consent had been given. Genomic DNA was extracted from peripheral blood leucocytes. PMP22, MPZ, MFN, and GJB1 mutations were previously excluded in the index case. Subsequently, a CMT gene panel screen was employed to identify candidate disease-causing variants.
Family 3
The family was evaluated in the University of Iowa CMT Clinic.
Informed consent was obtained from all individuals and the study obtained the approval of the Institutional Review Board at the University of Iowa. Neurological examination and neurophysiological studies were performed. The second version of the CMTNS (CMTNSv2) and CMT Exam Score (CMTESv2) [1] were employed to evaluate neuropathy. The SureSelect Human All Exon 50 MB Kit (Agilent, Santa Clara, CA, USA)) was used for in-solution enrichment, and the HiSeq 2500 instrument (Illumina) was used to produce 100 bp paired-end sequence reads. The BWA, Picard, and the GATK were used to align sequence reads and call variants. These data were imported into GEN-ESIS (GEM.app) (Gonzalez et al., 2015) for further analysis and filtering of variants.
The following HARS variants were identified in each of the three families: c.464T > G; p. Multiple-species amino-acid sequence alignments were generated using Clustal Omega software (Larkin et al., 2007) and annotated with quaternary structural information by ENDscript (Robert & Gouet, 2014 ( Figure 2F ).
Yeast complementation assays
Yeast complementation assays to study the functional consequences of HARS mutations were generated and performed as previously described (Vester et al., 2013 
Expression and purification of human HARS enzymes
Neuropathy-associated HARS mutations p.Ser356Asn, p.Tyr330Cys, and p.Val155Gly HARS containing plasmids were generated by purified by affinity and ion exchange chromatography as previously described (Abbott et al., 2017) . Purified proteins were visualized by on a 10% SDS-PAGE gel.
Multiple turnover aminoacylation kinetics
Multiple turnover aminoacylation assays were performed using a modified version of the Uhlenbeck-Wolfson assay as previously described (Abbott et al., 2017; Wolfson, Pleiss, & Uhlenbeck, 1998) . Multiple turnover experiments were conducted in a buffer composed of (50 mM HEPES pH 7.5, 150 KCl, 10 mM MgCl 2 , 5 mM ß-ME, 2 U/ml total radiolabeled product (aa + A76) according to Equation (1):
Differential scanning fluorimetry
The differential scanning fluorimetry (DSF) experiments were carried out as previously described (Abbott et al., 2017) . Briefly purified HARS proteins were incubated with 6× SYPRO orange dye and DSF buffer Scan rates were initiated at 26 • C and heated at increments of 1 • C per minute, to 95 • C while fluorescence intensity was measured every 1 • C. We fit the fluorescence data with GraphPad Prism 7 software as previously described (Abbott et al., 2017) to determine melting temperatures of HARS neuropathy-associated enzyme mutations and substrate complexes.
The melting temperature (T m ), defined as the midpoint of the protein unfolding transition curve, was determined using the Boltzman model as previously described (Niesen, Berglund, & Vedadi, 2007) .
GraphPad Prism 7 software was used to fit the fluorescence data (excluding data after maximal fluorescence intensity) to the Equation (2):
Analytical centrifugation sedimentation velocity experiments and analysis
Analytical centrifugation experiments were performed as previously described (Abbott et al., 2017 Beckman Optima XLI analytical ultracentrifuge using an An60Ti rotor and standard 2-channel epon centerpieces (Beckman-Coulter, Brea, CA, USA) and measured by UV intensity.
All data were examined with UltraScan-III ver. 3.5, release 2170 (Brookes E., 2006; Demeler et al., 2016) and hydrodynamic corrections for buffer density and viscosity was estimated to be 1.0019 g/ml and 0.998 cP, respectively. The partial specific volume of HARS (0.745 ml/g) was estimated by UltraScan from protein sequence analogous using methods outlined in Laue, Shah, Ridgeway, and Pelletier (1992) . Experimental sedimentation data were pre-processed by two-dimensional spectrum analysis (Brookes, Cao, & Demeler, 2010; Demeler, 2010; Schuck, 1999) and fitted by the parametrically constrained spectrum analysis (PCSA), using a straight-line parameterization coupled with a Monte Carlo approach Gorbet et al., 2014) . The calculations were performed on the Lonestar cluster at the Texas Advanced Computing Center at the University of Texas at Austin and on Comet and Gordon at San Diego Supercomputing Center.
RESULTS
Clinical and genetic analysis of patients with peripheral neuropathy
Family 1
A three-generation family of Persian-Jewish descent (living in Israel)
was identified with peripheral neuropathy ( Figure 4A ). Five affected individuals are present and the family displays an autosomal dominant inheritance pattern with male-to-male transmission. Figure 1A -C) and that is conserved from human to yeast ( Figure 5 ). p.Val155Gly HARS has not been previously reported nor has it been detected in the gnomAD database (Table 1) ( Lek et al., 2016) .
Family 2
A two-generation pedigree was identified with peripheral neuropathy ( Figure 4B ). The age of neuropathy onset for both patients was during childhood. Both individuals show a motor predominant phenotype, with distal motor deficit and atrophy, hammer toes, and pes cavus.
Both affected patients have mild sensory symptoms in the toes, with reduced vibration sense at the knees. Tendon reflexes were brisk in both patients. The mother (patient 1) is restricted to a wheelchair while her son (patient 2) walks with difficulty but without aid. The CMTNS for patient 1 was 22 and 9 for patient 2. The phenotype of patient 1 is likely exacerbated by concomitant diseases (diabetes, chemotherapy for melanoma, radiculitis secondary to herpes zoster, and Parkinson's disease). Nerve conduction studies show axonal motor-predominant neuropathy in both patients.
Targeted gene panel screening in Family 2 ( Figure 4B ) revealed two missense HARS variants in cis: p.Ser227Ala and p.Tyr330Cys.
These variants were previously reported as part of a larger study on CMT disease (Lupo et al., 2016) but the functional consequences of the mutations were not assessed. Both mutations segregate with the disease phenotype; however, p.Ser227Ala was deprioritized due to the number of alleles detected in gnomAD (37 alleles in 282,464 alleles total) and the lack of conservation of the affected residue (see Figure 5) . p.Tyr330Cys HARS affects an amino-acid residue in the catalytic core of the HARS enzyme ( Figure 1B ) that is conserved from human to bacteria ( Figure 5 ). p.Tyr330Cys has not been previously reported 
Family 3
A simplex pedigree was identified with two unaffected parents and a single daughter affected with peripheral neuropathy ( Figure 4C ). The Whole-exome sequencing was performed on the affected daughter in Family 3 ( Figure 4C ), which revealed p.Ser356Asn HARS as the only candidate disease-associated variant. Sanger sequencing revealed that this variant was inherited from the unaffected mother suggesting decreased penetrance or that this is a non-pathogenic variant.
p.Ser356Asn HARS is also found in the active site of the HARS enzyme ( Figure 1B and C) and that is conserved from human to yeast ( Figure 5 ).
p.Ser356Asn HARS has not been previously reported; however, it has been detected in the gnomAD database (five alleles in 277,222 chromosomes; Table 1 ) (Lek et al., 2016) . 
TA B L E 1 HARS variants identified in patients with peripheral neuropathy
F I G U R E 5
Neuropathy-associated HARS mutations are highly conserved. A: Multiple-species protein alignments were generated to assess the conservation of each affected amino-acid position. Complete amino-acid sequence alignment of human, mouse, worm, yeast, and bacterial HARS were generated with Clustal Omega and annotated with quaternary structural information with ENDscript (Robert & Gouet, 2014) . The position of known functional domains of the HARS protein indicated in blue (WHEP-TRS domain of unknown function), red (catalytic core), and yellow (tRNA binding domain) and motifs critical for substrate binding are indicated along the top. For each of the three variants, the affected amino acid is indicated by an * in the HARS protein sequence in multiple, evolutionarily diverse species. Note that strictly conserved residues are highlighted in red with white lettering while slightly conserved residues across multiple but not all species are red (Boeke, LaCroute, & Fink, 1984) . Thus, only yeast cells expressing a functional HTS1 allele from the pRS315 vector will grow in this assay.
The identified HARS mutations affect viability in yeast complementation studies
Yeast transformed with a WT HTS1 expression vector demonstrated significant growth, while those transformed with an empty vector did not ( Figure 3A) , consistent with HTS1 being an essential gene (Vester et al., 2013) . Yeast expressing p.Tyr330Cys or p.Ser356Asn Figure 3B ).This confirms a similar finding that was recently reported .
We next mutated the HARS expression construct to harbor the three missense mutations (p.Val155Gly, p.Tyr330Cys, or p.Ser356Asn) and found that p.Tyr330Cys and p.Ser356Asn HARS did not support any yeast cell growth indicating that they are functional null alleles (Figure 3B) . Interestingly, p.Val155Gly HARS supported growth, but in a manner that is severely reduced compared to WT HARS ( Figure 3B ).
These data indicate that p.Val155Gly HARS is a hypomorphic allele.
Combined, our in vivo functional analyses indicate that p.Val155Gly, p.Tyr330Cys, and p.Ser356Asn HARS are loss-of-function alleles.
Multiple-turnover kinetics identify specific catalytic deficiencies of HARS mutations
The results of the yeast complementation assays and the location of Table 2 ). By comparison, the p.Val155Gly HARS mutant exhibited a modest two-fold reduction in k cat ( Figure 7 and Table 2 ).
These results confirm and extend the previous yeast complementation and product formation assays.
When histidine was the variable substrate and tRNA and ATP were the fixed concentration substrates, the turnover numbers for each of the mutants were similar to the values obtained in experiments Table 2 . The plots are color coded as in Figure 6 : wild-type HARS (black diamonds, ⧫); p.Val155Gly HARS (green triangles, ⬧); p.Tyr330Cys HARS (red circles, •), and p.Ser356Asn HARS (blue squares, ■). When ATP was the variable substrate, none of the mutants reached a saturating velocity at the highest ATP concentration (5 mM). The inset shows linear fits of the V/S data for the mutants to allow an estimation of k cat /K M . Each point represents the mean of three independent experiments, and error bars indicate the standard error where tRNA was the variable substrate ( Figure 7 and Table 2 ). The most significant kinetic differences were seen with the p.Tyr330Cys and p.Val155Gly HARS mutants. The K M for histidine was elevated 25-fold for p.Tyr330Cys HARS, and at least 86-fold for p.Val155Gly HARS ( Figure 7 and Figure 7C ). Relative to WT HARS, all three mutants showed significant decreases in V/K M for ATP, corresponding to 342-fold for p.Val155Gly HARS, 866-fold for p.Ser356Asn HARS, and 2,549-fold for p.Tyr330Cys HARS (Table 2 ). Based on these results, we conclude that, for all three mutants, a major component of the attenuated catalytic activity originates from a significant increase in K M , for ATP. It is noteworthy that, while we were unable to achieve saturation at 5 mM ATP, we were able to reproduce k cat results with 10 mM ATP in both the tRNA and histidine titrations (Table 2 ). In summary, we conclude that the HARS neuropathyassociated mutations lead to significant decreases in catalytic activity, typically reflected in decreases in k cat and increases in the K M for ATP binding.
DSF reveals one out of three HARS mutations is unstable and two mutations have substrate binding defects
DSF is a useful technique that can be used to assess the melting temperature stabilizing effect of a substrate with respect to an enzyme, as well as aid in the evaluation of the effect of a potential pathogenic missense variant on protein structure (Abbott et al., 2017) . Previously, incubation of HARS with saturating concentrations of the histidine amino-acid ligand raised the thermal shift transition temperature by seven degrees (Abbott et al., 2017 Fahoum and Yang (1987) Values reported are the mean ± standard error of three independent experiments. a Data are for histidine in the pyrophosphate exchange reaction. (Abbott et al., 2017) . Values reported are the mean ± standard error of two independent experiments in triplicate. Values that are significantly different WT to Val155Gly are indicated as *** P < 0.0001 (extra sum-of-squares F test). a Relative to the apo form of the same enzyme. b Relative to the same form of WT HARS enzyme. kinetic data, there was an inverse relationship between the K M for histidine of a given mutant protein and the extent of temperature stability provided by incubation with histidine in the assay. As seen in Figure 8 and Table 3 For WT HARS, the ATP and tRNA-mediated temperature shifts are much smaller (2.04 • and 1.7 • , respectively) than that provided by histidine ( Figure 8 and Table 3 ). In the presence of saturating ATP (5 mM), all three neuropathy-associated mutations had slightly increased ∆T m values, corresponding to least 2 • C for p.Tyr330Cys and p.Ser356Asn, and 3 • C for p.Val155Gly (Table 3 ). In the presence of 20 M tRNA His , all three mutants exhibited 1 • C in ∆T m increases in stability (Table 3) .
TA B L E 3 Thermal stability of neuropathy-associated HARS variants and substrate complexes
Notably, none of the three mutants showed a significantly altered melting temperature in the presence of either ATP or tRNA, despite the fact that all three show substantially reduced apparent second order rate constants associated with ATP binding (Table 3) .
Analytical ultracentrifugation confirms that HARS neuropathy-associated mutations do not disrupt enzyme dimerization
Previous studies investigating mutations in the GARS gene linked to CMT have reported that a subset of the mutant substitutions lead to weaker tertiary interactions and thus reduced dimer stability (Nangle, . Given the location of the HARS mutants in the active site, we considered the possibility that the decreased activity of these mutants might be a consequence of reduced dimer stability. To address this hypothesis, we subjected highly purified preparations of each of the mutant proteins and a WT control to sedimentation velocity experiments at various loading concentrations. In these experiments, we monitored protein absorbance at 230 nm, allowing the experiments to be performed at concentrations that would be in the range of the equilibrium dissociation constant (K d )
for the dimer. As shown in Supp. Figure S1 , the molar mass distributions of the WT and mutant proteins were closely similar. For each mutant, a major species was observed that had a molar mass that was in excellent agreement with the dimer form of HARS (Table 4 and Supp. Figure S1 ). In none of the mutants was there a detectable amount of material corresponding to the monomeric form of the enzyme. On the basis of these results, we conclude that the pathophysiology of these mutants is unlikely to be the result of a weakened dimeric interface.
DISCUSSION
Mutations in five ARS genes were previously implicated in CMT disease (Jordanova et al., 2006; Latour et al., 2010; Safka Brozkova et al., 2015; Storkebaum, 2016; Tsai et al., 2017; Vester et al., 2013 
Strength of the evidence implicating the newly identified HARS mutations in neuropathy
Implicating ARS mutations in peripheral neuropathy requires data showing that the variants segregate with disease in large pedigrees and are absent at high frequencies in the general population. Indeed, the majority of previously implicated ARS mutations meet these criteria (Oprescu et al., 2017) . When genetic data are impossible to obtain, functional studies can be employed to predict pathogenicity, provided that the functional assays are informative. With respect to ARS mutations, enzyme kinetic and yeast complementation assays are informative for predicting mutational pathogenicity (Oprescu et al., 2017) . Several independent lines of evidence allow us to conclude that p.Val155Gly and p.Tyr330Cys HARS are the causal mutations in Family 1 and Family 2, respectively. Notably, the mutations segregate with the CMT phenotype in pedigrees (albeit in a small family for p.Tyr330Cys), occur at highly conserved amino acids, are absent from variant databases, and result in loss-of-function effects similar to other CMT-associated ARS variants. By contrast, the evidence for the role of p.Ser356Asn in the CMT phenotype in Family 3 is less convincing. Specifically, the patient's unaffected mother is heterozygous for p.Ser356Asn HARS, and this variant is present (albeit at a very low frequency) in the gnomAD variant database. However, the fact that p.Ser356Asn affects a highly conserved amino-acid residue and displays impaired function similar to validated, disease-associated ARS mutations strongly supports the conclusion that it may be a pathogenic variant (Safka Brozkova et al., 2015; Vester et al., 2013) .
One possibility is that p.Ser356Asn HARS has reduced penetrance similar to certain GARS mutations (Sivakumar et al., 2005) . This proposal is supported by the low frequency of validated, CMT-associated ARS mutations in the gnomAD variant database (e.g., p.Gly240Arg
GARS; https://gnomad.broadinstitute.org/variant/7-30649345-G-C;
Gly240Arg is equivalent to p.Gly294Arg on a longer protein isoform).
Conversely, it is possible that p.Ser356Asn is not the disease-causing mutation in Family 3 despite the deleterious effect on enzyme function. Thus, we conclude that p.Ser356Asn HARS is an excellent candidate for pathogenicity in Family 3, but that further genetic and phenotypic evidence is required to implicate this variant in CMT disease.
Structural justification for activity defects
All three of the amino-acid substitutions analyzed here alter amino acids located in the catalytic domain, consistent with their pronounced effect on aminoacylation. Visualization of these substitutions in the context of available X-ray structure of human HARS provides insights into potential structural and functional consequences. While Ser356
does not appear to be involved directly in substrate binding interactions, it may be important for positioning other amino-acid residues within the active site that are critical for binding of the ATP substrate.
ATP binding in the active site of HARS is dependent on magnesium ions that are coordinated to the non-bridging oxygens of the and phosphates of ATP, and the strictly conserved glutamate in Motif 2. In the human HARS histidine complex (no ATP), Ser356 is within 2.5Å
of Arg 388 (Figure 2A ), the conserved motif 3 arginine that (based on the E. coli complex) is predicted to interact with the gamma phosphate of ATP ( Figure 2B structures, and has different conformations in the different subunits of the asymmetric unit (Koh et al., 2014) . Hence, it is difficult to make definitive conclusions about the potential role of Ser356 in stabilizing interactions in the bound complex, and about the consequences of substitution with asparagine. In any event, the elevated K M for ATP seen with p.Ser356Asn could be seen as a likely outcome of a local disruption of contacts to the gamma phosphate.
The one mutant that would be predicted to have the most severe consequence for HARS function is p.Tyr330Cys, which substitutes a highly conserved tyrosine in the His A motif that constitutes part of the binding site for histidine ( Figure 5) . Notably, this residue has different conformations in the apo versus histidine bound human cytoplasmic HARS complex. In the apo complex without substrates (4 × 5O), Y330 adopts a conformation directed away from the active site, pointing toward solvent and donating a hydrogen bond to the main chain carbonyl of Gly108 ( Figure 2C ). In the complex of HARS with its aminoacid substrate, Y330 moves some 8Å to approach within 3.1 of the alpha-carbon of histidine ( Figure 2D ). In this bound conformation, Y330 may further stabilize the histidine binding pocket by engaging in a stacking interaction with the polar group of the neighboring tyrosine in position 331.
A similar effect may underlie the effect of p.Val155Gly on HARS function. Notably, this mutant exhibited a lower melting temperature than the other mutants, but the substitution had no effect on the association constant for the dimer. Analysis of the human HARS-histidine complex and comparison to the E. coli HisRS-histidinol ATP complex suggests that p.Val155Gly is unlikely to substitute a residue that interacts directly with ATP ( Figure 2E ). However, Val155 is in the region of the active site near where ATP binds, and the valine can potentially make a CH-interaction with the neighboring hydrophobic Phe171 in the active site ( Figure 2E ). Phe171 in human HARS corresponds to Phe125 in the E. coli enzyme (Arnez et al., 1995) , which makes a critical stacking interaction with the adenine ring ( Figure 2F (Table 3) , and the elevated K M for histidine (Table 2 ).
The vast majority of ARS mutations impair enzyme activity
Previous studies examining the links between mutations in ARS genes and CMT have addressed the question of whether mutations lead to a significant loss of aminoacylation activity, or a change in an as yet undetermined secondary function. The biochemical analyses in this study indicate that CMT-linked HARS mutations confer significant reductions in aminoacylation function, in accordance with what has been described for AARS mutations (McLaughlin, et al., 2012) . These AARS mutations, like the described HARS mutations, also fail to complement yeast growth over a background where the endogenous yeast gene has been disrupted (Oprescu et al., 2017) . Thus, for AARS and HARS mutations, the link to CMT appears to be directly associated with a loss of aminoacylation function.
The link between CMT and reduced ARS function is slightly less clear for two other ARS genes, GARS and YARS. In these cases, multiple mutations are linked to the disease, some of which have clear reductions in aminoacylation, and some of which appear to retain significant activity. In GARS, 12 GARS mutations have been associated with CMT disease, the majority of which are deleterious to enzyme function (Oprescu et al., 2017) . In the case of YARS, two mutants are reported to have significantly reduced activity (Jordanova et al., 2006) but one (p.Glu196Lys) appears to be much more active, or even unaffected (Froelich & First, 2011) . However, the p.Glu196Lys mutant and another CMT-associated mutation at the same codon (p.Glu196Gln)
were unable to fully support yeast cell growth in complementation studies (Gonzaga-Jauregui et al., 2015; Jordanova et al., 2006) . Furthermore, studies employing a D. melanogaster model of CMT show that, despite its near WT activity in vitro, p.Glu196Lys YARS leads to decreased protein synthesis rates in flies (Niehues et al., 2015) . These and other results suggest that, in the context of specialized cell types, the consequences of a particular human pathogenic ARS mutation may be difficult to predict a priori. Mutations that lead to decreased activity may have limited phenotypic impact owing to the fact that, under normal conditions, protein synthesis can be met by less than 100% activity of a given tRNA synthetase. Conversely, a mutation that has limited impact on aminoacylation in vitro may exert more deleterious impact in vivo, owing to folding defects that promote proteotoxic stress. Discrepancies may arise as a consequence of additional interactions with other proteins and/or RNAs that are necessary to execute all phases of protein synthesis. Moving forward, a critical question to be addressed for each CMT-related ARS allele is if protein synthesis is affected as a direct downstream consequence of impaired aminoacylation.
Proposed gain-of-function effects of ARS mutations
Clearly more research is needed to resolve the effect of CMTassociated ARS mutations on enzyme function. As an alternative to loss-of-function mechanisms, multiple gain-of-function hypotheses have been proposed, specifically for GARS mutations (Motley, Talbot, & Fischbeck, 2010) . For example, a mechanism in which mutant monomeric GARS binds to the VEGF receptor neuropilin-1 and alters neuronal signaling has been proposed in the context of a mouse model (He et al., 2015) . As yet, the relevance of this model to human disease-associated mutations is not fully clear. However, three human mutant GARS proteins (p.Glu71Gly, p.Leu129Pro, and p.Gly240Arg)
were shown to bind to neuropilin-1 in vitro. Additionally, it was argued that the propensity of mutant GARS to bind to neuropilin-1 was linked to weakened dimer formation . While the findings reported here do not explicitly address the neuropilin-1 hypothesis, our characterization of HARS mutant proteins indicates that, despite a loss of canonical catalytic function, there is no evidence for weakened dimerization (Supp. Figure S1 ). It should also be noted that, despite the linkage of over 80 loci to CMT disease, neither mutations in neuropilin-1 nor in any of the ligands for this receptor have been identified in patients with CMT disease.
CONCLUSIONS
Here, we present data that for the first time link impaired enzyme activity to HARS-associated peripheral neuropathy. This observation dictates considerations of how altered tRNA charging might affect peripheral nerve function. Human peripheral nerve axons can extend more than a meter in length, and transport of essential proteins to the cell periphery is essential for maintaining axon function (Giuditta, Dettbarn, & Brzin, 1968) . There is increasing evidence of local protein translation along axons and at synapses, but the role of ARSs in this process is still not well understood (Holt & Schuman, 2013) . Moving forward, it will be important to directly test if CMT-associated ARS mutations alter specific aspects of protein translation. In summary, additional studies are required to determine if CMT-associated ARS mutations act via a loss-of-function or gain-of-function mechanism; we suggest that these two mechanisms are not mutually exclusive. Our study presents data that further supports a loss-of-function molecular pathology and provides key data, newly applied methods, and novel reagents for studying the pathological mechanism of ARS-associated human disease.
